SG11202011434SA - Methods for the treatment of bladder cancer - Google Patents

Methods for the treatment of bladder cancer

Info

Publication number
SG11202011434SA
SG11202011434SA SG11202011434SA SG11202011434SA SG11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA
Authority
SG
Singapore
Prior art keywords
treatment
methods
bladder cancer
bladder
cancer
Prior art date
Application number
SG11202011434SA
Other languages
English (en)
Inventor
Dae-Shik Kim
Frank Fang
Atsushi Endo
Hyeong-Wook Choi
Ming-Hong Hao
Xingfeng Bao
Kuan-Chun Huang
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11202011434SA publication Critical patent/SG11202011434SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202011434SA 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer SG11202011434SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679495P 2018-06-01 2018-06-01
US201962826347P 2019-03-29 2019-03-29
PCT/US2019/034933 WO2019232392A1 (en) 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
SG11202011434SA true SG11202011434SA (en) 2020-12-30

Family

ID=67138025

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011434SA SG11202011434SA (en) 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer

Country Status (11)

Country Link
US (1) US12251394B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801561B1 (cg-RX-API-DMAC7.html)
JP (1) JP7335277B2 (cg-RX-API-DMAC7.html)
KR (1) KR102993248B1 (cg-RX-API-DMAC7.html)
CN (1) CN112512531B (cg-RX-API-DMAC7.html)
AU (1) AU2019277679B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020024605A2 (cg-RX-API-DMAC7.html)
CA (1) CA3101623A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020012964A (cg-RX-API-DMAC7.html)
SG (1) SG11202011434SA (cg-RX-API-DMAC7.html)
WO (1) WO2019232392A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
EP4398901A1 (en) 2021-09-09 2024-07-17 Eisai R&D Management Co., Ltd. Biomarkers for sting agonists and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
JP2016538344A (ja) * 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
EP3233089A4 (en) 2014-12-17 2018-11-14 Lipogen LLC Method of treating cancer with cgamp or cgasmp
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
TWI808092B (zh) 2017-08-30 2023-07-11 中國大陸商北京軒義醫藥科技有限公司 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド

Also Published As

Publication number Publication date
JP2021525758A (ja) 2021-09-27
US20210205348A1 (en) 2021-07-08
EP3801561B1 (en) 2025-03-19
CA3101623A1 (en) 2019-12-05
JP7335277B2 (ja) 2023-08-29
CN112512531B (zh) 2024-04-09
CN112512531A (zh) 2021-03-16
WO2019232392A1 (en) 2019-12-05
MX2020012964A (es) 2021-02-16
BR112020024605A2 (pt) 2021-04-06
AU2019277679B2 (en) 2024-11-28
EP3801561A1 (en) 2021-04-14
US12251394B2 (en) 2025-03-18
AU2019277679A1 (en) 2020-12-24
KR20210015937A (ko) 2021-02-10
KR102993248B1 (ko) 2026-07-21

Similar Documents

Publication Publication Date Title
IL267795A (en) Combined treatment for cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL256224B (en) Combined therapy for cancer treatment
IL258521A (en) Combination of treatments for cancer treatment
ZA202206743B (en) Therapy for the treatment of cancer
GB201903546D0 (en) Cancer treatment
ZA202005847B (en) Cancer therapy
IL277981A (en) Cancer treatment methods
SG11202011117VA (en) Treatment of cancer
SI3416957T1 (sl) Spojine 6-heterociklil-4-morfolin-4-ilpiridin-2-ona, uporabne za zdravljenje raka in diabetesa
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL281600B2 (en) Cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
EP3548007A4 (en) METHOD OF TREATMENT OF CANCER
IL266993A (en) Combined therapy for cancer treatment
IL285466A (en) Cancer treatment
IL284162A (en) Integrated healing for cancer treatment
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
GB201820098D0 (en) Methods of cancer treatment
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
GB201820975D0 (en) Methods of cancer treatment
GB201819920D0 (en) Cancer treatment
IL253642A0 (en) Combined treatment for cancer
EP3270898A4 (en) Methods for the treatment of bladder cancer